Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors

Inclusion Criteria:

* Histologically or cytologically confirmed diagnosis of a solid tumor malignancy that is not responsive to standard therapy(ies) or for which there is no approved therapy
* Patients must have acceptable laboratory requirements
* Left ventricular ejection fraction as measured by echocardiogram or multiple-gated acquisition scan that is above the institutional lower level of normal or greater than 50%
* Has experienced resolution of toxic effect(s) of the most recent prior chemotherapy and/or prior surgical and radiation treatment
* Must be able to understand and give written informed consent and comply with study procedures

Exclusion Criteria:

* If the patient has brain metastasis, they must have stable neurologic status without the use of steroids or on a stable or decreasing dose of steroids
* Presence of clinically significant gastrointestinal abnormalities that may affect the absorption of study treatments
* A medical condition that precludes adequate study treatment compliance or assessment, or increases patient risk in the opinion of the Investigator
* Patient has a concomitant cardiovascular issue that precludes adequate study treatment compliance or increases patient risk
* Diagnosis of immunodeficiency or receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug
* Prior chemotherapy, targeted small molecule therapy, or radiation therapy within 4 weeks prior to study
* Prior anti-cancer monoclonal antibody within 4 weeks prior to baseline
* Currently enrolled in another investigational study
* Has disease that is suitable for approved therapy administered with curative intent